Prostate Cancer Medicine Market

1. Prostate Cancer Medicine Global Opportunity Analysis and Industry Forecast, 2017-2023

2. Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise, ethnicity (African American men), and old age contribute to its occurrence. Increase in geriatric population globally and rise in prevalence of prostate cancer due to hectic lifestyle, ethnicity, unhealthy diet, and lack of awareness are expected to fuel the market growth. According to the National Cancer Institute, in the U.S., prostate cancer is estimated to cause about 26,730 deaths in 2017. In addition, R&D activities in the field of prostate cancer drugs and emerging economies in developing countries are expected to present new opportunities during the forecast period.

3. However, stringent government regulations, high cost of prostate cancer medicines and low awareness of prostate cancer restrict the growth. • The prostate cancer medicine market is segmented on the basis of drug type and geography. Based on drug type, it is divided into hormonal therapy drugs, chemotherapy drugs, immunotherapy drugs, and target therapy drugs. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning • Technologically sophisticated and reliable insights through well audited and veracious research methodology • Sovereign research proceeds that present a tangible depiction of marketplace

4. Key Benefits: • The study provides an in-depth analysis of the global prostate cancer medicine market, with current trends and future estimations to elucidate the investment pockets. • Comprehensive analysis of factors that drive and restrict the growth of the market is provided. • The report presents a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities. • Extensive analysis of different segments facilitates to understand various products of the market. • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.

5. Prostate Cancer Medicine Market Key Segments: • By Drug Type • Hormonal Therapy Drugs • LHRH Antagonists • LHRH Analogs • Antiandrogens • Pipeline Drugs for Hormonal Therapy • Chemotherapy Drugs • Off-patent Drugs • Patented Drugs • Immunotherapy Drugs • Off-patent Drugs • Patented Drugs • Target Therapy Drugs • Angiogenesis Inhibitor • Apoptosis Inducing • Signal Transduction Inhibitor

6. Prostate Cancer Medicine Market Key Segments: • By Geography • North America • U.S. • Canada • Mexico • Europe • Germany • France • UK • Italy • Spain • Rest of Europe • Asia-Pacific • Japan • China • India • Rest of Asia-Pacific